PDF(Sci-hub)
Abstract：
Dabigatran is an orally active direct thrombin inhibitor, initially approved by FDA for the prophylaxis of stroke and systemic embolism in the setting of non-valvular atrial fibrillation (NVAF). Major bleeding is its most common adverse event which is of great concern. However, other types of adverse events such as esophagitis, esophageal ulcer, exanthem and pustular eruptions were reported increasingly in recent years. We present a case of immune hemolytic anemia (IHA) due to dabigatran use in a 72-year-old male with NVAF. This new and rare reported type of adverse event associated with dabigatran suggests that dabigatran may be a new cause of drug-induced immune hemolytic anemia (DIIHI).
摘要：
达比加群是一种口服活性的直接凝血酶抑制剂，FDA最初批准用于预防非瓣膜性心房颤动（NVAF）的卒中和全身性栓塞。大出血是其最常见的不良事件，备受关注。然而,其他类型的不良事件，如食管炎，食管溃疡,近年来，有越来越多的人报道exanthem和脓疱爆发。我们介绍了一例因使用达比加群而导致的免疫性溶血性贫血（IHA）在一名72岁的NVAF男性中。这种与达比加群相关的新的和罕见的不良事件类型表明达比加群可能是药物诱导的免疫性溶血性贫血（DIIHI）的新原因。
